RELAPSING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hope for kids with MS: ublituximab trial launches
Disease control Not yet recruitingThis study tests the drug ublituximab in children aged 10 to 18 with relapsing multiple sclerosis (MS). It compares ublituximab to another drug, fingolimod, to see which better controls relapses. The trial involves 240 participants and will also monitor long-term safety and effec…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE2, PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
MS patients switch drugs to save immune defenses
Disease control Not yet recruitingThis study follows 115 adults with multiple sclerosis who are switching from ocrelizumab to ofatumumab because their antibody levels dropped. Researchers want to see if the switch stops or slows that decline over 24 months. The goal is to better manage immune health while still t…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
MS patients may soon get a simpler shot option
Disease control Not yet recruitingThis study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
MS drug delivery showdown: belly vs. thigh, pen vs. syringe
Disease control Not yet recruitingThis study tests a drug called ublituximab, given as a shot under the skin, in 350 people with relapsing multiple sclerosis. Researchers want to see how the drug moves through the body when injected in different spots (like the belly or thigh) and whether an autoinjector pen work…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New study aims to find which MS drug better fights fatigue
Knowledge-focused Not yet recruitingThis study will follow 100 adults with multiple sclerosis who are starting either teriflunomide or dimethyl fumarate as part of their routine care. Over 12 months, researchers will measure how well participants can walk and think during sustained activities, along with their repo…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS
Sponsor: TC Erciyes University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC